| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K J Villanueva, A Vultur, JT Lee, R Somasundaram, M Fukunaga-Kalabis, ... Cancer cell 18 (6), 683-695, 2010 | 1477 | 2010 |
| RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss, JS Reis-Filho, ... New England Journal of Medicine 366 (3), 207-215, 2012 | 1194 | 2012 |
| RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors PA Oberholzer, D Kee, P Dziunycz, A Sucker, N Kamsukom, R Jones, ... Journal of clinical oncology 30 (3), 316, 2012 | 462 | 2012 |
| Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study A Ribas, R Gonzalez, A Pavlick, O Hamid, TF Gajewski, A Daud, ... The lancet oncology 15 (9), 954-965, 2014 | 304 | 2014 |
| Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial O Klein, D Kee, A Nagrial, B Markman, C Underhill, M Michael, L Jackett, ... JAMA oncology 6 (9), 1405-1409, 2020 | 176 | 2020 |
| Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers O Klein, D Kee, B Markman, M Michael, C Underhill, MS Carlino, L Jackett, ... Clinical Cancer Research 26 (17), 4454-4459, 2020 | 134 | 2020 |
| Circulating tumor DNA analysis and functional imaging provide complementary approaches for comprehensive disease monitoring in metastatic melanoma SQ Wong, JM Raleigh, J Callahan, IA Vergara, S Ftouni, A Hatzimihalis, ... Precision Oncology 1, 1-14, 2017 | 108 | 2017 |
| The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma B Lee, A Wong, D Kee, P Neeson, M Shackleton, G McArthur, S Sandhu Annals of Oncology 27 (6), 1174-1177, 2016 | 65 | 2016 |
| Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma M Alexander, JD Mellor, G McArthur, D Kee Medical Journal of Australia 201 (1), 49-53, 2014 | 64 | 2014 |
| Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A … EL Mitchell, PKH Lau, C Khoo, D Liew, J Leung, B Liu, A Rischin, ... European Journal of Cancer 105, 88-102, 2018 | 59 | 2018 |
| Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma J Lewin, L Sayers, D Kee, I Walpole, A Sanelli, L Te Marvelde, ... Annals of Oncology 29 (7), 1569-1574, 2018 | 58 | 2018 |
| Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors D Kee, JR Zalcberg Therapeutic Advances in Medical Oncology 4 (5), 255-270, 2012 | 51 | 2012 |
| Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma K Nesic, O Kondrashova, RM Hurley, CD McGehee, CJ Vandenberg, ... Cancer research 81 (18), 4709-4722, 2021 | 48 | 2021 |
| FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment A Iravani, MM Osman, AM Weppler, R Wallace, A Galligan, A Lasocki, ... European journal of nuclear medicine and molecular imaging 47, 2776-2786, 2020 | 44 | 2020 |
| Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy O Klein, D Kee, B Markman, MS Carlino, C Underhill, J Palmer, D Power, ... Cancer Cell 39 (5), 592-593, 2021 | 43 | 2021 |
| Immunotherapy of melanoma D Kee, G McArthur European Journal of Surgical Oncology (EJSO) 43 (3), 594-603, 2017 | 40 | 2017 |
| Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538 O Klein, C Senko, MS Carlino, B Markman, L Jackett, B Gao, C Lum, ... Oncoimmunology 10 (1), 1908771, 2021 | 30 | 2021 |
| Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature A Gunjur, O Klein, D Kee, J Cebon Journal for immunotherapy of cancer 7, 1-7, 2019 | 29 | 2019 |
| RAF1 rearrangements are common in pancreatic acinar cell carcinomas OWJ Prall, V Nastevski, H Xu, CRE McEvoy, JHA Vissers, DJ Byrne, ... Modern Pathology 33 (9), 1811-1821, 2020 | 21 | 2020 |
| Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma C Robert, MS Carlino, C McNeil, A Ribas, JJ Grob, J Schachter, M Nyakas, ... Journal of Clinical Oncology 41 (24), 3998-4003, 2023 | 20 | 2023 |
Grant McArthurPeter MacCallum Cancer CentreVerified email at petermac.org
